Bbva Compass Bancshares Inc. increased its position in shares of Core Laboratories N.V. (NYSE:CLB) by 8.0% during the second quarter, Holdings Channel reports. The institutional investor owned 10,551 shares of the oil and gas company’s stock after buying an additional 780 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Core Laboratories N.V. were worth $1,068,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in CLB. Parallel Advisors LLC increased its position in shares of Core Laboratories N.V. by 33.4% in the first quarter. Parallel Advisors LLC now owns 891 shares of the oil and gas company’s stock worth $101,000 after buying an additional 223 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Core Laboratories N.V. during the first quarter valued at $106,000. Advisory Services Network LLC acquired a new position in shares of Core Laboratories N.V. during the first quarter valued at $118,000. FNY Managed Accounts LLC acquired a new position in shares of Core Laboratories N.V. during the first quarter valued at $123,000. Finally, First Bank & Trust increased its position in shares of Core Laboratories N.V. by 2.7% in the first quarter. First Bank & Trust now owns 1,411 shares of the oil and gas company’s stock valued at $163,000 after buying an additional 37 shares during the period.

Shares of Core Laboratories N.V. (NYSE:CLB) opened at 101.96 on Friday. The firm’s 50-day moving average price is $102.90 and its 200 day moving average price is $109.93. Core Laboratories N.V. has a 1-year low of $96.30 and a 1-year high of $125.83. The stock has a market cap of $4.50 billion, a P/E ratio of 62.55 and a beta of 1.60.

Core Laboratories N.V. (NYSE:CLB) last issued its quarterly earnings data on Monday, July 24th. The oil and gas company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.01. The company had revenue of $163.90 million for the quarter, compared to analyst estimates of $168.23 million. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.35 earnings per share. On average, equities analysts expect that Core Laboratories N.V. will post $2.10 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 14th. Shareholders of record on Monday, July 17th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.16%. The ex-dividend date is Thursday, July 13th. Core Laboratories N.V.’s payout ratio is 134.15%.

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2017/08/05/bbva-compass-bancshares-inc-has-1-07-million-position-in-core-laboratories-n-v-clb.html.

Several brokerages recently weighed in on CLB. Zacks Investment Research downgraded Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research note on Tuesday, April 11th. Loop Capital upgraded Core Laboratories N.V. from a “hold” rating to a “buy” rating and boosted their target price for the stock from $125.00 to $130.00 in a research note on Friday, April 21st. ABN Amro upgraded Core Laboratories N.V. to a “hold” rating in a research note on Friday, April 21st. Scotiabank set a $136.00 target price on Core Laboratories N.V. and gave the stock a “hold” rating in a research note on Saturday, April 22nd. Finally, BidaskClub upgraded Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $117.58.

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.